康希諾生物-B(06185.HK):克威莎納入世界衞生組織緊急使用清單
格隆匯5月20日丨康希諾生物-B(06185.HK)發佈公吿,世界衞生組織將重組新型冠狀病毒疫苗(5型腺病毒載體)(商品名:克威莎)列入世衞組織的緊急使用清單。克威莎經世衞組織緊急使用清單程序評估,此決定基於世衞組織資格預審專家(包括來自世界各地的監管專家)對該疫苗的質量、安全性、有效性數據和風險管理計劃的審查。最終風險效益評估由世衞組織緊急使用清單的技術諮詢小組進行。其認為克威莎符合世衞組織認定的防護COVID-19的標準,且該疫苗帶來的好處遠大於風險。
根據披露,克威莎採用基因工程方法構建,以複製缺陷型5型腺病毒為載體,可表達新型冠狀病毒S抗原。克威莎不含防腐劑、佐劑或動物源成分。緊急使用清單是新冠疫苗實施計劃疫苗供應的先決條件,還有助於各國加快對引進和接種COVID-19疫苗的監管批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.